dalteparin has been researched along with Esophageal Squamous Cell Carcinoma in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Esophageal Squamous Cell Carcinoma: A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current treatment approaches for esophageal cancer are associated with poor survival, and there are ongoing efforts to find new and more effective therapeutic strategies." | 2.90 | A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer. ( Akhavan Rezayat, K; Avan, A; Fanipakdel, A; Ferns, GA; Gholami, A; Hosseini, S; Javadinia, SA; Joudi Mashhad, M; Taghizadeh Kermani, A; Zardadi, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taghizadeh Kermani, A | 1 |
| Hosseini, S | 1 |
| Fanipakdel, A | 1 |
| Joudi Mashhad, M | 1 |
| Akhavan Rezayat, K | 1 |
| Zardadi, M | 1 |
| Gholami, A | 1 |
| Javadinia, SA | 1 |
| Ferns, GA | 1 |
| Avan, A | 1 |
1 trial available for dalteparin and Esophageal Squamous Cell Carcinoma
| Article | Year |
|---|---|
A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Enoxaparin; Esophageal Ne | 2019 |